Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10794048 | 1.00 | CA14 (0.43) | CA14CA12MAPTALDH1A1L3MBTL1 | |
| SCHEMBL5389558 | 0.86 | MME (0.36) | CA14CA12MAPTALDH1A1L3MBTL1 | |
| SCHEMBL5626080 | 0.86 | MME (0.36) | CA14CA12MAPTALDH1A1L3MBTL1 | |
| SCHEMBL4689740 | 0.86 | MME (0.36) | CA14CA12MAPTALDH1A1L3MBTL1 | |
| SCHEMBL7491237 | 0.86 | MAPT (0.37) | CA14CA12MAPTALDH1A1L3MBTL1 | |
| SCHEMBL7439996 | 0.86 | MAPT (0.37) | CA14CA12MAPTALDH1A1L3MBTL1 | |
| SCHEMBL15461486 | 0.85 | MAPT (0.34) | CA14CA12MAPTALDH1A1L3MBTL1 | |
| SCHEMBL8910730 | 0.84 | CA14 (0.43) | CA14CA12 | |
| SCHEMBL9800590 | 0.84 | CA14 (0.38) | CA14CA12 | |
| SCHEMBL15461474 | 0.84 | NPSR1 (0.32) | MAPTALDH1A1L3MBTL1NPSR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962934-B2 | Substituted amino carboxamides for the treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030166580-A1 | Substituted amino carboxamides for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166580-A1 | Substituted amino carboxamides for the treatment of alzheimer's disease | BACE1, BACE2, APP | CA14 1471/4885CA12 1161/4885MAPT 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.